Cart
sales@molnova.com
RAS activator compound 1
CAS No. 1579978-17-8
RAS activator compound 1( —— )
Catalog No. M12257 CAS No. 1579978-17-8
RAS activator compound 1 is a small molecule RAS activator compound that increases the rate of SOS-catalyzed nucleotide exchange in vitro with EC50 of 14 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRAS activator compound 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionRAS activator compound 1 is a small molecule RAS activator compound that increases the rate of SOS-catalyzed nucleotide exchange in vitro with EC50 of 14 uM.
-
DescriptionRAS activator compound 1 is a small molecule RAS activator compound that increases the rate of SOS-catalyzed nucleotide exchange in vitro with EC50 of 14 uM; targets SOS1 induced biphasic modulation of RAS-GTP and ERK phosphorylation levels, through negative feedback on SOS1 that regulates the interaction between SOS1 and GRB2.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetRas
-
RecptorRas
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1579978-17-8
-
Formula Weight449.983
-
Molecular FormulaC25H28ClN5O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1CN(CCC1NC(=O)C(CC2=CNC3=CC=CC=C32)N)CC4=CNC5=C4C=C(C=C5)Cl
-
Chemical Name(S)-2-amino-N-(1-((5-chloro-1H-indol-3-yl)methyl)piperidin-4-yl)-3-(1H-indol-3-yl)propanamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Howes JE, et al. Mol Cancer Ther. 2018 May;17(5):1051-1060.
2. Burns MC, et al. Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3401-6.
molnova catalog
related products
-
PDEδ-IN-99
PDEδ-IN-99 is a novel potent K-Ras-PDEδ inhibitor that binds to the farnesyl binding pocket of PDEδ with Kd of 8±4 nM.
-
AMG-510
Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state.
-
MRTX1257
MRTX1257 (MRTX-1257, MRTX 1257) is a potent, selective, covalent and irreversible inhibitor of KRAS G12C.
